See also this year's filing and all EDGAR filings for this company.
PDF Report 0001533040_2014_Phio_Pharmaceuticals_Corp.pdf
Logs
| warning | No LiabilitiesAndStockholdersEquity node found | input.sec.calculation_linkbase.edgar_model_mapping | {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'DepositsAssetsNoncurrent', 'CashAndCashEquivalentsAtCarryingValue', 'RestrictedCashAndCashEquivalents', 'ShortTermInvestments', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'DeferredRevenue', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'DeferredRevenueCurrent', 'CapitalLeaseObligationsCurrent'))"} |
Graph
Absolute values for 0001533040, Phio Pharmaceuticals Corp
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 14,743,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 177,000 |
| 3 | remainder_Assets | 18,000 |
| 4 | LiabilitiesCurrent | 2,076,000 |
| 5 | LiabilitiesNoncurrent | 0 |
| 6 | remainder_Liabilities | 0 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 3,697,000 |
| 9 | ResearchAndDevelopmentExpense | 17,651,000 |
| 10 | remainder_Expenses | 0 |
| 11 | remainder_Revenues | 399,000 |
| 12 | remainder_NetIncome | 24,000 |
| 13 | remainder_ComprehensiveNetIncome | 0 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 14,938,000 |
| 1 | Liabilities | 2,076,000 |
| 2 | Expenses | 21,348,000 |
| 3 | Revenues | 399,000 |
| 4 | StockholdersEquity | 12,862,000 |
| 5 | NetIncome | -20,925,000 |
| 6 | ComprehensiveNetIncome | -20,925,000 |
| 7 | BaseVar | 19,392,500 |
| 8 | EconomicCapitalRatiobeforeLimitedLiability | 0.836 |
| 9 | EconomicCapitalRatio | 2.17 |
Edgar->Model Mapping
Feature Distribution
Change over Time
